2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

4:30PM-6:00PM: Abstract Number: 1910

Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow

4M121: Spondyloarthritis Including Psoriatic Arthritis – Clinical IV: Axial Spondyloarthritis Translational Research (1908–1913)

4:30PM-6:00PM: Abstract Number: 1859

Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients

4M111: Imaging of Rheumatic Diseases I (1854–1859)

4:30PM-6:00PM: Abstract Number: 1890

Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)

4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

4:30PM-6:00PM: Abstract Number: 1909

miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients

4M121: Spondyloarthritis Including Psoriatic Arthritis – Clinical IV: Axial Spondyloarthritis Translational Research (1908–1913)

4:30PM-6:00PM: Abstract Number: 1869

Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders

4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

4:30PM-6:00PM: Abstract Number: 1871

Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury

4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

4:30PM-6:00PM: Abstract Number: 1850

Needs Assessment of Rheumatology Fellowship Program Directors on the Need for a Health Disparities Curriculum for Our Fellowship Programs

4M110: Healthcare Disparities in Rheumatology (1848–1853)

4:30PM-6:00PM: Abstract Number: 1870

NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis

4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

4:30PM-6:00PM: Abstract Number: 1921

Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

4M125: Pediatric Rheumatology: Outcomes & Quality of Life (1920–1925)

4:30PM-6:00PM: Abstract Number: 1908

Preliminary Identification of Arthritis-Associated Microbiota in Experimental Spondyloarthritis

4M121: Spondyloarthritis Including Psoriatic Arthritis – Clinical IV: Axial Spondyloarthritis Translational Research (1908–1913)

4:30PM-6:00PM: Abstract Number: 1878

Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice

4M115: Pain Mechanisms – Basic & Clinical Science (1878–1883)

4:30PM-6:00PM: Abstract Number: 1853

Racial Differences in Highly Effective Contraceptive Use Among Medicaid Beneficiaries with SLE

4M110: Healthcare Disparities in Rheumatology (1848–1853)

4:30PM-6:00PM: Abstract Number: 1848

Racial Disparities in Septic and Aseptic Total Knee Replacement Revision Risk: A Study Using Four State-wide Inpatient Databases

4M110: Healthcare Disparities in Rheumatology (1848–1853)

4:30PM-6:00PM: Abstract Number: 1916

Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis

4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

4:30PM-6:00PM: Abstract Number: 1898

Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study

4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.